### Deals channel feed #### [GSK took advantage of ASCO dip to get discount on Nuvalent](https://endpoints.news/gsk-took-advantage-of-asco-dip-to-get-discount-on-nuvalent/) 3 days ago #### [Sciwind has two Western partners for its obesity drug, but is open to more](https://endpoints.news/sciwind-has-two-western-partners-for-its-obesity-drug-but-is-open-to-more/) 3 days ago #### [Kardigan's $320M IPO pitch: Three borrowed heart drugs, one proven cardio CEO](https://endpoints.news/kardigan-plans-320m-ipo-for-heart-drugs-as-nasdaq-listings-gain-steam/) 4 days ago #### ['Going for our own moonshot': Parabilis CEO on biotech's record IPO](https://endpoints.news/parabilis-ceo-mathai-mammen-on-biotechs-record-ipo/) 5 days ago #### [Novartis and Orionis strike second molecular glue deal for $40M upfront](https://endpoints.news/novartis-and-orionis-strike-second-molecular-glue-deal-for-40m-upfront/) 5 days ago #### [GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B](https://endpoints.news/gsk-to-acquire-nuvalent-and-its-two-cancer-drugs-under-fda-review-for-10-6b/) 6 days ago #### [Incyte's Meury sees $2B Vega deal as a step in blood treatments beyond Jakafi](https://endpoints.news/incyte-ceo-sees-2b-vega-deal-aiding-a-post-jakafi-future/) Last week #### [Treeline to go public via reverse merger with Standard BioTools](https://endpoints.news/treeline-to-go-public-via-reverse-merger-with-standard-biotools/) Last week #### [J&J makes $1B move for Firefly Bio, Carolyn Bertozzi's twist on ADCs in KRAS field](https://endpoints.news/jj-makes-1b-move-for-firefly-bio-carolyn-bertozzis-twist-on-adcs-in-kras-field/) Last week #### [Incyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront deal](https://endpoints.news/incyte-to-buy-bleeding-disorder-biotech-vega-therapeutics-in-1-25b-upfront-deal/) Last week #### [Nurix to work with Roche on BTK degrader in pact worth up to $2.3B](https://endpoints.news/nurix-to-work-with-roche-on-btk-degrader-in-pact-worth-up-to-2-3b/) Last week #### [Parabilis Medicines charts $413M IPO to back peptide pipeline](https://endpoints.news/parabilis-medicines-charts-413m-ipo-to-back-peptide-pipeline/) Last week #### [Alnylam signs its first AI discovery deal with RNA specialist Inceptive](https://endpoints.news/alnylam-to-pay-30m-upfront-to-ai-startup-inceptive-in-rna-rd-deal/) Last week #### [Regeneron doubles down on CytomX after other pharmas walked away](https://endpoints.news/regeneron-doubles-down-on-cytomx-after-other-pharmas-walked-away/) Last week #### [Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases](https://endpoints.news/lilly-strikes-deal-with-ascidian-worth-up-to-1-9b-for-rna-editing-in-kidney-diseases/) Last week #### [Travere pays Everest $112M upfront to grow rare kidney disease pipeline](https://endpoints.news/travere-pays-everest-112m-upfront-to-grow-rare-kidney-disease-pipeline/) Last week #### [Exclusive: Bipartisan group of lawmakers unveil new bill to restrict China biotech](https://endpoints.news/citing-dangerous-deals-lawmakers-propose-china-restrictions/) Last week #### [After being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listing](https://endpoints.news/after-being-ditched-by-candid-rallybio-finds-avenzo-to-take-its-nasdaq-listing/) 2 weeks ago #### [Servier signs $1.55B upfront deal for Edgewise's muscular dystrophy assets](https://endpoints.news/servier-signs-1-55b-upfront-deal-for-edgewises-muscular-dystrophy-assets/) 2 weeks ago #### [Lilly enters GLP-2 space in deal with Korea's Hanmi, also forges discovery pact with China's Haisco](https://endpoints.news/lilly-licenses-glp-2-asset-from-korean-biotech-hanmi-for-75m-upfront/) 2 weeks ago #### [Pfizer strikes Innovent deal worth up to $10.5B for a dozen cancer programs](https://endpoints.news/pfizer-strikes-innovent-deal-worth-up-to-10-5b-for-a-dozen-cancer-programs/) 3 weeks ago #### [Apogee lands $800M royalty deal with Blackstone to move Dupixent rival toward Phase 3](https://endpoints.news/apogee-secures-blackstone-capital-to-move-dupixent-rival-into-phase-3/) 3 weeks ago #### [WuXi Bio signs manufacturing deal with Viridian as Biosecure threat continues to erode](https://endpoints.news/wuxi-bio-signs-deal-to-manufacture-viridians-thyroid-eye-disease-drug/) 3 weeks ago #### [Three vaccine biotechs to be bought by Lilly for up to $3.8B](https://endpoints.news/lilly-to-acquire-three-vaccine-biotechs-for-up-to-3-8b/) 3 weeks ago